Table 3.

Association between Various PAP therapies and Hospitalizations with Matched Medication only (control) Groups

	Any Hospitalization*		COPD-Related Hospitalization*
	N	OR (95% CI), p	N	OR (95% CI), p
BILEVEL-PAP	298,792		298,792
Treatment Group	9,156	0.40 (0.37, 0.43), <0.001	9,156	0.45 (0.38, 0.52), <0.001
Medication only (control) Group	289,636	0.47 (0.46, 0.48), <0.001	289,636	0.39 (0.38, 0.40), <0.001
CPAP	504,069		504,069
Treatment Group	39,385	0.67 (0.65, 0.70), <0.001	39,385	0.52 (0.47, 0.59), <0.001
Medication only (control) Group	464,684	0.51 (0.51, 0.52), <0.001	464,684	0.36 (0.35, 0.37), <0.001
NIPPV	80,952		80,952
Treatment Group	315	0.21 (0.15, 0.30), <0.001	315	0.29 (0.18, 0.47), <0.001
Medication only (control) Group	80,637	0.59 (0.58, 0.60), <0.001	80,637	0.58 (0.56, 0.60), <0.001

^*Adjusted for the propensity score, age, sex, region, insurance type, acute respiratory failure, Alzheimer’s and related dementia, anxiety or bipolar disorder, asthma, atrial fibrillation, chronic kidney disease, coronary heart disease, congestive heart failure, depression, diabetes, hypercholesterolemia or hyperlipidemia, hypertension, hypoxemia, insomnia, ischemic heart disease, lung cancer, morbid obesity, osteoarthritis, osteoporosis or rheumatoid arthritis and related disease, schizophrenia and other psychotic disorders, stroke, SABA or LABA, SAMA or LAMA, SABA+ACS, methylxanthines, ICS, ICS+LABA, oral prednisone, smoking cessation, and oxygen